Peptides / Sexual health and hormones

Synthetic analog · 10 amino acids · 1,322.5 Da

Nafarelin

ApprovedBanned in sport

Nafarelin (Synarel) is a GnRH agonist nasal spray approved in the US for endometriosis and early puberty, also approved in EU countries, and banned in sport. Studies in people tested it on sex hormones, fertility and bone, and tracked side effects. PepBank shows 448 results on nafarelin from 69 studies in people, and 101 from animal and lab studies. The strongest evidence is a randomized trial in people. Data as of 2026-10-30.

Also known as Synarel

10 amino acids, from first to lastEHWSYXLRPG

Evidence level: Large trials in people448 of 549 results come from studies in people, including randomized trials.

Results in people

448

82% of 549 results

Results in animals

17% of 549 results

Results in lab cells

2% of 549 results

From computer models

0% of 549 results

Overview

Nafarelin at a glance

What it is	Synthetic analog, 10 amino acids
Approval	Approved in the US and EU (Synarel, 1990)
In sport	Banned in sport (WADA S2.2.1)
Studies	87 studies with results. 82 of them gave nafarelin, with 549 results. 448 in people91 in animals10 in lab cells
Best study in people	Randomized controlled trial with 307 people (1992)
Clinical trials	10 registered: 4 active or planned, 0 with posted results
Community use	Management of endometriosis in women aged 18 years and older

The science

What is nafarelin?

Nafarelin is a ten-residue GnRH agonist analog containing D-2-naphthylalanine at position 6.

Amino acids in one chain

The history of nafarelin

1984
The oldest paper on nafarelin in PepBank is from 1984.
1990February
FDA approved Synarel for management of endometriosis, including pain relief and reduction of endometriotic lesions. Label experience is limited to women aged 18 years and older. Also approved for central precocious puberty in children of both sexes.
2002September
A registered trial of nafarelin started (NCT00034047).

Nafarelin structure and chemistry

The key facts about the molecule. Long codes are in the closed section below.

Sequence, 10 amino acidsFrom the first amino acid to the last

−E1HWSY5XL+RPG10

Darker means more water-repelling+ and − show charge in the bodyOutlined: changed amino acid

Structure

Nafarelin is a synthetic analog of 10 amino acids, with no ring, 2 changed amino acids.

Formula

C₆₆H₈₃N₁₇O₁₃

Molecular weight

1,322.5 g/mol

CAS number

76932-56-4

Target

Gonadotropin-releasing hormone receptor (gene GNRHR): agonistEvidence: The label identifies GnRH agonism. UniProt P30968 identifies the human GNRHR receptor.

Development

Highest phase: past the trial stage (see status).

Identifiers

PubChem 25077405, UNII 1X0094V6JV, DrugBank DB00666

Full sequence, SMILES and InChIKey

InChIKey
RWHUEXWOYVBUCI-ITQXDASVSA-N

SMILES
CC(C)C[C@@H](C(=O)N[C@@H](CCCN=C(N)N)C(=O)N1CCC[C@H]1C(=O)NCC(=O)N)NC(=O)[C@@H](CC2=CC3=CC=CC=C3C=C2)NC(=O)[C@H](CC4=CC=C(C=C4)O)NC(=O)[C@H](CO)NC(=O)[C@H](CC5=CNC6=CC=CC=C65)NC(=O)[C@H](CC7=CN=CN7)NC(=O)[C@@H]8CCC(=O)N8

See charge, composition and 3D structure on the Scientific page

The evidence

What nafarelin studies show

Results grouped by what the studies measured. Each card shows where its results come from.

Large trials in people448 of 549 results come from studies in people, including randomized trials.

Sex hormones and fertility

335 results · 268 in people · 67 animal

In ICSI patients, mean egg retrieval was 10.5 with nafarelin versus 10.2 with leuprolide, with no significant difference. Journal of assisted reproduction and genetics, 2001

Top results

In ICSI patients, mean egg retrieval was 10.5 with nafarelin versus 10.2 with leuprolide, with no significant difference. (Journal of assisted reproduction and genetics, 2001)
In patients with endometriosis, nafarelin and danazol suppressed oestradiol similarly. (The Australian & New Zealand journal of obstetrics & gynaecology, 1991)
In women with endometriosis, nafarelin and buserelin were linked to similar CA-125 reductions in a retrospective analysis. (Fertility and sterility, 1992)

Bones and joints

51 results · 51 in people

Bone density loss was lower with nafarelin than leuprolide depot. The Journal of reproductive medicine, 1997

Top results

Bone density loss was lower with nafarelin than leuprolide depot. (The Journal of reproductive medicine, 1997)
In women with endometriosis, low-dose nafarelin alone increased urinary calcium excretion. (The Journal of clinical endocrinology and metabolism, 1990)
Decreasing-dose nafarelin caused less bone density loss than full-dose treatment. (Fertility and sterility, 2000)

Survival and serious illness

17 results · 14 in people · 3 animal

In women with endometriosis, endometriosis score change did not differ between nafarelin and goserelin. Gynecological endocrinology, 2000

Top results

In women with endometriosis, endometriosis score change did not differ between nafarelin and goserelin. (Gynecological endocrinology, 2000)
In patients with endometriosis, nafarelin and danazol reduced disease scores similarly. (The Australian & New Zealand journal of obstetrics & gynaecology, 1991)
In patients with endometriosis, nafarelin and danazol did not differ significantly in treatment efficacy. (Fertility and sterility, 1990)

Cholesterol and blood fats

11 results · 11 in people

Nafarelin affected lipid profiles more favorably than danazol. Journal of the Chinese Medical Association, 2005

Top results

Nafarelin affected lipid profiles more favorably than danazol. (Journal of the Chinese Medical Association, 2005)
In patients with endometriosis, total HDL cholesterol increased slightly during nafarelin treatment. (The Journal of clinical endocrinology and metabolism, 1989)
In patients with endometriosis, nafarelin users did not show the HDL decrease seen with danazol. (The New England journal of medicine, 1988)

Hormones

11 results · 11 in people

In women with endometriosis, nafarelin alone at 200 micrograms reduced the free index of active vitamin D. The Journal of clinical endocrinology and metabolism, 1990

Top results

In women with endometriosis, nafarelin alone at 200 micrograms reduced the free index of active vitamin D. (The Journal of clinical endocrinology and metabolism, 1990)
In women treated for gynecological conditions, nafarelin did not significantly change total ACTH secretion. (Human reproduction, 1993)
In women with endometriosis, nafarelin alone at 400 micrograms reduced the free index of active vitamin D. (The Journal of clinical endocrinology and metabolism, 1990)

Pain

8 results · 8 in people

In women with endometriosis, efficacy did not differ between 6 months of nafarelin and 3 months followed by placebo. Fertility and sterility, 1995

Top results

In women with endometriosis, efficacy did not differ between 6 months of nafarelin and 3 months followed by placebo. (Fertility and sterility, 1995)
Among symptomatic endometriosis patients, 94% improved with nafarelin compared with 91% with danazol. (American journal of obstetrics and gynecology, 1990)
In women with advanced endometriosis, nafarelin and placebo produced similar reductions in multidimensional pain scores. (American journal of obstetrics and gynecology, 1994)

Nafarelin has 224 linked papers. PepBank read up to 120 of the most-cited studies that gave it to people, up to 20 other studies, and the main trials.

All 87 nafarelin studies by area Open the Scientific page

Key nafarelin studies

Studies in people come first, then studies in animals and in the lab.

People
Nafarelin for endometriosis: a large-scale, danazol-controlled trial of efficacy and safety, with 1-year follow-up. The Nafarelin European Endometriosis Trial Group (NEET)
1992 · Fertility and sterility · 307 people · cited by 12
7 results
People
Prospective randomized comparison of ovarian blockade with nafarelin versus leuprolide during ovarian stimulation with recombinant FSH in an ICSI program
Franco et al. 2001 · Journal of assisted reproduction and genetics · 238 people · cited by 9
7 results
People
Administration of nasal nafarelin as compared with oral danazol for endometriosis. A multicenter double-blind comparative clinical trial
Henzl et al. 1988 · The New England journal of medicine · 213 people · cited by 226
9 results
People
A comparative study of the acceptability and effect of goserelin and nafarelin on endometriosis
Bergqvist et al. 2000 · Gynecological endocrinology : the official journal of the International Society of Gynecological Endocrinology · 213 people · cited by 20
7 results
People
Nafarelin vs. leuprolide acetate depot for endometriosis. Changes in bone mineral density and vasomotor symptoms. Nafarelin Study Group
Agarwal et al. 1997 · The Journal of reproductive medicine · 192 people · cited by 26
5 results

All 87 Nafarelin studies

Nafarelin clinical trials

ClinicalTrials.gov lists 10 trials of nafarelin. 4 are active or planned, and 0 have posted results. PepBank does not show trial results.

Solid bars are dates that happened. Hatched bars are planned dates. Data from ClinicalTrials.gov.

Luteal Phase Support With GnRH Agonist After GnRH Agonist Triggering in IVF/ICSI Cycles

Phase 3recruiting652 planned

Natural Versus HRT Cycles in Frozen Embryo Replacement Treatment

Phase 4completed159 people

Intranasal Nafarelin For Triggering Oocyte Maturation

Phase 4recruiting154 planned

All 2 Nafarelin trials

Status and safety

Is nafarelin approved?

FDA

United States

Approved

An approved medicine contains it.

EMA

European Union

Approved

An approved medicine contains it.

WADA

Sport

Banned

On the 2026 Prohibited List, section S2.2.1.

Yes. Approved in the US and EU (Synarel, 1990). The FDA label for Synarel says: “Management of endometriosis, including pain relief and reduction of endometriotic lesions” Banned in sport (WADA S2.2.1).

Laws and labels change, so check the regulator for the current status.

Nafarelin side effects and safety

PepBank has 117 safety results from studies of nafarelin. 102 of them come from studies in people.

Safety results from studies (117)

In patients with endometriosis, the liver enzyme increase was smaller with nafarelin than danazol. (Fertility and sterility, 1992)
In patients with endometriosis, hot flashes were more frequent with nafarelin than danazol. (The New England journal of medicine, 1988)
In women with endometriosis, adverse events did not differ significantly between nafarelin and goserelin. (Gynecological endocrinology, 2000)
Bone density loss was lower with nafarelin than leuprolide depot. (The Journal of reproductive medicine, 1997)
In women with endometriosis, nafarelin was linked to fewer days with moderate or severe hot flashes than leuprolide. (The Journal of reproductive medicine, 1999)
Overall adverse event rates were similar with nafarelin and danazol, except laboratory-related events. (Journal of the Chinese Medical Association, 2005)
Treatment tolerance was the same with preoperative and postoperative nafarelin. (European journal of obstetrics, gynecology, and reproductive biology, 1998)
In patients with endometriosis, nafarelin and danazol had similar rates of side effects. (The Australian & New Zealand journal of obstetrics & gynaecology, 1991)
Decreasing-dose nafarelin produced fewer adverse effects than full-dose treatment. (Fertility and sterility, 2000)
In patients with pelvic endometriosis, secondary symptoms were milder and better tolerated with nafarelin than with goserelin. (Ginecologia y obstetricia de Mexico, 2000)
In patients with endometriosis, hot flushes were more frequent with nafarelin than danazol. (Fertility and sterility, 1990)
In women awaiting hysterectomy, hot flushes occurred in 61% with nafarelin versus 35% with placebo. (Human reproduction, 1995)
Hot flush frequency after the first month did not differ between the two nafarelin doses. (Gynecological endocrinology, 1997)
In women undergoing IVF, side effects were few and comparable with nafarelin and buserelin. (Human reproduction, 1994)
In women with endometriosis, spinal bone density declined similarly in both nafarelin duration groups. (American journal of obstetrics and gynecology, 1994)
Lumbar bone density decreased from baseline with repeat nafarelin treatment. (American journal of obstetrics and gynecology, 1997)
In regularly ovulating women, nafarelin treatment had no serious side effects. (Journal of steroid biochemistry, 1985)
In premenopausal women, bone turnover markers increased to postmenopausal levels in both nafarelin dose groups. (The Journal of clinical endocrinology and metabolism, 1988)
Three women using lower-dose nafarelin stopped early, mainly because of hot flushes. (Fertility and sterility, 1986)
In women receiving nafarelin, two subjects did not complete treatment. (Contraception, 1985)
In women with endometriosis, spinal bone density fell during nafarelin treatment, then returned toward baseline. (American journal of obstetrics and gynecology, 1995)
No side effects were recorded in the nafarelin or buserelin IVF cycles. (Gynecological endocrinology, 1996)
In women with endometriosis, spinal bone mineral decreased after 6 months of nafarelin treatment. (Clinical endocrinology, 1990)
In women with endometriosis, estradiol fell during nafarelin and danazol treatment. (Gynecological endocrinology, 1990)

See every safety result on the Scientific page

Doses studied (40 shown)

The doses that these studies used. They are not recommendations.

Dose as reported	Class	Species	Route	Duration	Design	Source
200 micrograms twice daily	Human	human	intranasal	6 months	Randomized trial in people · n = 307	1992
200 microg twice a day	Human	human	nasal	From menstrual cycle day 21 until the day of HCG	Randomized trial in people · n = 238	Franco 2001
400 or 800 micrograms per day	Human	human	nasal spray	six months	Randomized trial in people · n = 213	Henzl 1988
200 micrograms twice daily	Human	human	intranasal	6 months	Randomized trial in people · n = 192	Agarwal 1997
800 microg/day	Human	human	intranasal	Not reported	Randomized trial in people · n = 181	Simberg 1998
200 micrograms twice daily	Human	human	nasal spray	3 months	Randomized trial in people · n = 166	Ylikorkala 1995
200 micrograms twice daily	Human	human	Not reported	6 months	Randomized trial in people · n = 93	Hornstein 1997
400 micrograms/day	Human	human	nasal	3 months	Randomized trial in people · n = 75	Parazzini 1994
200 microg three times daily, reduced to 200 microg twice daily at ovarian stimulation	Human	human	intranasal	Not reported	Randomized trial in people · n = 64	Elgendy 1998
200 microg twice a day	Human	human	intranasal	6 months	Randomized trial in people · n = 53	Audebert 1998
400 micrograms daily	Human	human	intranasal	6 months	Randomized trial in people · n = 49	Fraser 1991
400 micrograms per dose	Human	human	intranasal	Not reported	Randomized trial in people · n = 26	Schmidt-Sarosi 1995
200 micrograms twice daily	Human	human	intranasal	Not reported	Randomized trial in people · n = 24	Dantas 1994
200 microgram twice daily for 4 weeks, then 200 microgram daily for 20 weeks	Human	human	Not reported	24 weeks	Randomized trial in people · n = 15	Tahara 2000
200 or 400 micrograms each 12 hours	Human	human	Not reported	Not reported	Randomized trial in people · n = 15	Calvo 2000
400 micrograms daily	Human	human	Not reported	6 months	Randomized trial in people	Kennedy 1990
200 micrograms twice daily	Human	human	intranasal	Not reported	Randomized trial in people	Lockwood 1995
200 micrograms daily	Human	human	Not reported	6 months	Randomized trial in people	Bergqvist 1997
800 or 400 micrograms/d	Human	human	Not reported	6 months	Randomized trial in people	Hickok 1991
800 micrograms/d	Human	human	Not reported	6 months	Randomized trial in people	Hickok 1991
200 microg twice daily for 7 days, then 200 microg daily	Human	human	Not reported	Not reported	Randomized trial in people	Takeuchi 2001
800 micrograms/d	Human	human	intranasal	Not reported	Randomized trial in people	Loh 1999
200 micrograms twice daily	Human	human	Not reported	6 months	Trial in people without random groups · n = 194	Rolland 1990
200 micrograms twice a day	Human	human	intranasal	3 or 6 months	Trial in people without random groups · n = 173	Orwoll 1994
400 mcg/day	Human	human	intranasal	3 months	Trial in people without random groups · n = 45	Adamson 1997
600 micrograms daily	Human	human	Not reported	Not reported	Trial in people without random groups · n = 40	Tanos 1995
600 mcg/d initially, stopped after 5 days of hMG stimulation	Human	human	Not reported	Not reported	Trial in people without random groups · n = 36	Schachter 2001
125 or 250 micrograms daily	Human	human	intranasal	3 months	Trial in people without random groups · n = 30	Gudmundsson 1984
125 or 250 micrograms once daily	Human	human	intranasal	3 months	Trial in people without random groups · n = 30	Nillius 1985
single dose of 1, 5, 20 or 100 micrograms	Human	human	subcutaneous	Not reported	Trial in people without random groups · n = 28	Monroe 1985
200 or 400 micrograms/day	Human	human	Not reported	6 months	Trial in people without random groups · n = 25	Johansen 1988
125 micrograms daily	Human	human	intranasal	Not reported	Trial in people without random groups · n = 25	Gudmundsson 1986
125 or 250 micrograms daily	Human	human	intranasal	6 months	Trial in people without random groups · n = 24	Brenner 1985
250 micrograms daily	Human	human	intranasal	Not reported	Trial in people without random groups · n = 22	Gudmundsson 1986
400 micrograms/day	Human	human	intranasal	Not reported	Trial in people without random groups · n = 22	Avrech 1996
200 micrograms/day	Human	human	Not reported	6 months	Trial in people without random groups · n = 16	Johansen 1988
25 micrograms	Human	human	intravenous	Not reported	Trial in people without random groups · n = 15	Chaplin 1992
400 micrograms	Human	human	intranasal	Not reported	Trial in people without random groups · n = 15	Chaplin 1992
0.2 microgram/kg	Human	human	subcutaneous	Not reported	Trial in people without random groups · n = 13	Rosenfield 1986
400 micrograms daily	Human	human	Not reported	Not reported	Trial in people without random groups · n = 12	Välimäki 1989

From the community

How people use it

What people report online. It comes from forums and guides, not from studies.

Community-reported. Not tested in trials.

The US label describes Synarel nafarelin acetate nasal solution. This record selects its endometriosis regimen for women aged 18 years and older.

Reported routines and cautions

What people use it for

Management of endometriosis in women aged 18 years and olderS1

Reported regimens

Regimens that community sources report for Nafarelin. Community-reported, not tested in trials.
Context	Route	Amount	How often	How long	Agreement	Sources
Synarel nafarelin acetate nasal solution for endometriosis in women aged 18 years and olderOfficial label dosing of an approved product	intranasal sprayMetered nasal solution containing 2 mg/mL expressed as nafarelin base. Prime a new pump before first use.	200 mcg per dose	one spray into one nostril in the morning and one into the other nostril in the evening	six months	Single official US label source.	S1

Cautions

The label describes loss of bone mineral density and an initial stimulatory phase.S1

Status notes

The EMA list dated 2018-10-04 records national authorisations for Synarel and Synarela. It does not establish central EMA authorisation or current availability. Current country-specific authorisation status was not independently established.S2

Community sources

S1Synarel US prescribing information (opens in a new tab)dailymed.nlm.nih.gov
S2EMA regulatory information (opens in a new tab)ema.europa.eu

Gaps

No separate non-vendor community regimen with verified quantities is retained. This record covers one selected US label regimen. It does not cover all label instructions, patient groups or warnings.

Questions and more

Ask a question about nafarelin

The answer links to every study it uses.

What does the evidence say about nafarelin?Is nafarelin tested in people?Compare with Triptorelin (Trelstar, Decapeptyl)Compare with Oxytocin

Sources

Database: PepBank data for nafarelin (data version 308560)
Regulator: FDA status record
Regulator: EMA status record
Regulator: WADA status record
Trial registry: ClinicalTrials.gov
Community: community sources (forums and guides), as summarized in the PepBank community file

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

PepBank is a research reference. Talk to a doctor before you use any peptide.

Ask your AI about nafarelin

Nafarelin

ApprovedBanned in sport

Also known as Synarel

What it is

Synthetic analog, 10 amino acids

Approval

Approved in the US and EU (Synarel, 1990)

In sport

Banned in sport (WADA S2.2.1)

Studies

87 studies with results. 82 of them gave nafarelin, with 549 results.
448 in people91 in animals10 in lab cells

Best study in people

Randomized controlled trial with 307 people (1992)

Clinical trials

10 registered: 4 active or planned, 0 with posted results

Community use

Management of endometriosis in women aged 18 years and older

Dose as reported

Class

Species

Route

Duration

Design

Source

200 micrograms twice daily

Human

human

intranasal

6 months

Randomized trial in people · n = 307

1992

200 microg twice a day

Human

human

nasal

From menstrual cycle day 21 until the day of HCG

Randomized trial in people · n = 238

Franco 2001

400 or 800 micrograms per day

Human

human

nasal spray

six months

Randomized trial in people · n = 213

Henzl 1988

200 micrograms twice daily

Human

human

intranasal

6 months

Randomized trial in people · n = 192

Agarwal 1997

800 microg/day

Human

human

intranasal

Not reported

Randomized trial in people · n = 181

Simberg 1998

200 micrograms twice daily

Human

human

nasal spray

3 months

Randomized trial in people · n = 166

Ylikorkala 1995

200 micrograms twice daily

Human

human

Not reported

6 months

Randomized trial in people · n = 93

Hornstein 1997

400 micrograms/day

Human

human

nasal

3 months

Randomized trial in people · n = 75

Parazzini 1994

200 microg three times daily, reduced to 200 microg twice daily at ovarian stimulation

Human

human

intranasal

Not reported

Randomized trial in people · n = 64

Elgendy 1998

200 microg twice a day

Human

human

intranasal

6 months

Randomized trial in people · n = 53

Audebert 1998

400 micrograms daily

Human

human

intranasal

6 months

Randomized trial in people · n = 49

Fraser 1991

400 micrograms per dose

Human

human

intranasal

Not reported

Randomized trial in people · n = 26

Schmidt-Sarosi 1995

200 micrograms twice daily

Human

human

intranasal

Not reported

Randomized trial in people · n = 24

Dantas 1994

200 microgram twice daily for 4 weeks, then 200 microgram daily for 20 weeks

Human

human

Not reported

24 weeks

Randomized trial in people · n = 15

Tahara 2000

200 or 400 micrograms each 12 hours

Human

human

Not reported

Randomized trial in people · n = 15

Calvo 2000

400 micrograms daily

Human

human

Not reported

6 months

Randomized trial in people

Kennedy 1990

200 micrograms twice daily

Human

human

intranasal

Not reported

Randomized trial in people

Lockwood 1995

200 micrograms daily

Human

human

Not reported

6 months

Randomized trial in people

Bergqvist 1997

800 or 400 micrograms/d

Human

human

Not reported

6 months

Randomized trial in people

Hickok 1991

800 micrograms/d

Human

human

Not reported

6 months

Randomized trial in people

Hickok 1991

200 microg twice daily for 7 days, then 200 microg daily

Human

human

Not reported

Randomized trial in people

Takeuchi 2001

800 micrograms/d

Human

human

intranasal

Not reported

Randomized trial in people

Loh 1999

200 micrograms twice daily

Human

human

Not reported

6 months

Trial in people without random groups · n = 194

Rolland 1990

200 micrograms twice a day

Human

human

intranasal

3 or 6 months

Trial in people without random groups · n = 173

Orwoll 1994

400 mcg/day

Human

human

intranasal

3 months

Trial in people without random groups · n = 45

Adamson 1997

600 micrograms daily

Human

human

Not reported

Trial in people without random groups · n = 40

Tanos 1995

600 mcg/d initially, stopped after 5 days of hMG stimulation

Human

human

Not reported

Trial in people without random groups · n = 36

Schachter 2001

125 or 250 micrograms daily

Human

human

intranasal

3 months

Trial in people without random groups · n = 30

Gudmundsson 1984

125 or 250 micrograms once daily

Human

human

intranasal

3 months

Trial in people without random groups · n = 30

Nillius 1985

single dose of 1, 5, 20 or 100 micrograms

Human

human

subcutaneous

Not reported

Trial in people without random groups · n = 28

Monroe 1985

200 or 400 micrograms/day

Human

human

Not reported

6 months

Trial in people without random groups · n = 25

Johansen 1988

125 micrograms daily

Human

human

intranasal

Not reported

Trial in people without random groups · n = 25

Gudmundsson 1986

125 or 250 micrograms daily

Human

human

intranasal

6 months

Trial in people without random groups · n = 24

Brenner 1985

250 micrograms daily

Human

human

intranasal

Not reported

Trial in people without random groups · n = 22

Gudmundsson 1986

400 micrograms/day

Human

human

intranasal

Not reported

Trial in people without random groups · n = 22

Avrech 1996

200 micrograms/day

Human

human

Not reported

6 months

Trial in people without random groups · n = 16

Johansen 1988

25 micrograms

Human

human

intravenous

Not reported

Trial in people without random groups · n = 15

Chaplin 1992

400 micrograms

Human

human

intranasal

Not reported

Trial in people without random groups · n = 15

Chaplin 1992

0.2 microgram/kg

Human

human

subcutaneous

Not reported

Trial in people without random groups · n = 13

Rosenfield 1986

400 micrograms daily

Human

human

Not reported

Trial in people without random groups · n = 12

Välimäki 1989

Context

Route

Amount

How often

How long

Agreement

Sources

Synarel nafarelin acetate nasal solution for endometriosis in women aged 18 years and olderOfficial label dosing of an approved product

intranasal sprayMetered nasal solution containing 2 mg/mL expressed as nafarelin base. Prime a new pump before first use.

200 mcg per dose

one spray into one nostril in the morning and one into the other nostril in the evening

six months

Single official US label source.

Nafarelin

Nafarelin at a glance

What is nafarelin?

The history of nafarelin

Nafarelin structure and chemistry

What nafarelin studies show

Sex hormones and fertility

Bones and joints

Survival and serious illness

Cholesterol and blood fats

Hormones

Pain

Key nafarelin studies

Nafarelin clinical trials

Is nafarelin approved?

Nafarelin side effects and safety

How people use it

What people use it for

Reported regimens

Cautions

Status notes

Community sources

Ask a question about nafarelin

Related peptides

Sources

Nafarelin

Nafarelin at a glance

What is nafarelin?

The history of nafarelin

Nafarelin structure and chemistry

What nafarelin studies show

Sex hormones and fertility

Bones and joints

Survival and serious illness

Cholesterol and blood fats

Hormones

Pain

Key nafarelin studies

Nafarelin clinical trials

Is nafarelin approved?

Nafarelin side effects and safety

How people use it

What people use it for

Reported regimens

Cautions

Status notes

Community sources

Ask a question about nafarelin

Related peptides

Sources